Sage Therapeutics secures $3.1bn worth licensing deal for zuranolone and SAGE-217 with Biogen
Sage Therapeutics has secured a global collaboration and licensing deal worth up to $3.1 billion with Biogen for two of its drug candidates intended for the treatment of depression and movement disorders. Under the terms of the deal, the two US pharma companies will jointly develop and commercialize zuranolone (SAGE-217) for major depressive disorder (MDD), […]